JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ezeamuzie, C. I.
Right arrow Articles by Al-Hage, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ezeamuzie, C. I.
Right arrow Articles by Al-Hage, M.

Vol. 284, Issue 1, 25-31, 1998

Differential Effects of Salbutamol and Salmeterol on Human Eosinophil Responses1

Charles I. Ezeamuzie and Mary Al-Hage

Department of Pharmacology and Toxicology, Faculty of Medicine, Kuwait University, Kuwait

In the treatment of bronchial asthma, salmeterol is believed to have a greater anti-inflammatory activity than salbutamol. To determine whether the comparative effects of these drugs on eosinophil function are the basis of their differential anti-inflammatory properties, we studied the effect of the two drugs on interleukin-5 (IL-5) and 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF)-induced O2- release and adherence to fibronectin-coated plates, as well as the C5a- and N-formylmethionyl-leucyl-phenylalanine (FMLP)-induced degranulation of purified human blood eosinophils in vitro. Salmeterol significantly inhibited IL-5-induced O2- release in a concentration-dependent manner with an IC50 of 2.2 × 10-6 M (95% CI, 1.6-2.7 × 10-6 M) and a maximal inhibition of about 70%. In contrast, salbutamol had no significant effect even at 10-5 M. Both drugs significantly inhibited PAF-induced O2- generation, but salmeterol was approximately 20 times more potent than salbutamol. Salmeterol also significantly inhibited adherence induced by both IL-5 and PAF, whereas salbutamol had no significant effect on adherence induced by both agents. Both drugs failed to block C5a-induced eosinophil peroxidase release, whereas for FMLP-induced release, salbutamol, but not salmeterol, produced significant inhibition. Unlike salbutamol, all the actions of salmeterol were independent of beta-2 adrenoceptors. These results confirm that human eosinophils can be modulated directly by beta-2 adrenoceptor agonists, but that salmeterol and salbutamol have differential effects which depend on both the stimulus used and the response being measured and that the reportedly greater in vivo anti-inflammatory effect of salmeterol may reflect its superior ability to inhibit eosinophil O2- release and adherence, rather than degranulation.

0022-3565/98/2841-0025$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
N. A. Maris, K. F. van der Sluijs, S. Florquin, A. F. de Vos, J. M. Pater, H. M. Jansen, and T. van der Poll
Salmeterol, a {beta}2-receptor agonist, attenuates lipopolysaccharide-induced lung inflammation in mice
Am J Physiol Lung Cell Mol Physiol, June 1, 2004; 286(6): L1122 - L1128.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Myo, X. Zhu, S. Myou, A.Y. Meliton, J. Liu, E. Boetticher, A.T. Lambertino, C. Xu, N.M. Munoz, and A.R. Leff
Additive blockade of {beta}2-integrin adhesion of eosinophils by salmeterol and fluticasone propionate
Eur. Respir. J., April 1, 2004; 23(4): 511 - 517.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. I. EZEAMUZIE, J. SUKUMARAN, and E. PHILIPS
Effect of Wortmannin on Human Eosinophil Responses in Vitro and on Bronchial Inflammation and Airway Hyperresponsiveness in Guinea Pigs in Vivo
Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1633 - 1639.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. C. KIPS and R. A. PAUWELS
Long-acting Inhaled beta 2-Agonist Therapy in Asthma
Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 923 - 932.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Fujishige, J. Kotera, H. Michibata, K. Yuasa, S.-i. Takebayashi, K. Okumura, and K. Omori
Cloning and Characterization of a Novel Human Phosphodiesterase That Hydrolyzes Both cAMP and cGMP (PDE10A)
J. Biol. Chem., June 25, 1999; 274(26): 18438 - 18445.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
M. A. Giembycz and M. A. Lindsay
Pharmacology of the Eosinophil
Pharmacol. Rev., June 1, 1999; 51(2): 213 - 340.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Yuasa, J. Kotera, K. Fujishige, H. Michibata, T. Sasaki, and K. Omori
Isolation and Characterization of Two Novel Phosphodiesterase PDE11A Variants Showing Unique Structure and Tissue-specific Expression
J. Biol. Chem., September 29, 2000; 275(40): 31469 - 31479.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.